2025
Comparison of clinical symptoms and symptom structure across different onset ages in schizophrenia inpatients
Liu Z, Wang X, Chen W, Huang J, Tong J, Wang J, Liu R, Deng H, Yang K, Li W, Chen S, Xie T, Tian L, Yang F, Tian B, Li Y, Li C, Tan Y. Comparison of clinical symptoms and symptom structure across different onset ages in schizophrenia inpatients. Schizophrenia Research 2025, 277: 177-184. PMID: 40073617, DOI: 10.1016/j.schres.2025.03.015.Peer-Reviewed Original ResearchConceptsEarly-onset schizophreniaLate-onset schizophreniaPositive and Negative Syndrome ScaleAge of onset groupsSymptom network structureNegative symptomsSchizophrenia inpatientsSymptom networksSymptom severityNegative Syndrome ScaleSevere negative symptomsClinical symptom profilesOnset groupTreatment outcomesDevelopment of personalized treatment strategiesPoor treatment outcomesGeneral psychopathologyPositive symptomsSyndrome ScaleSymptom structureDisorganized thoughtsBridge symptomsSchizophrenia patientsSchizophreniaSymptom profilesEffect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials
Jerene D, van Kalmthout K, Levy J, Alacapa J, Deyanova N, Dube T, Mganga A, Tasca B, Bogdanov A, Efo E, Gamazina K, Garfin A, Kochanov V, Leung A, Madden N, Maraba N, McQuaid C, Mleoh L, Onjare B, Powers R, Terleiva Y, van Rest J, Gebhard A, Fielding K, Charalambous S. Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials. The Lancet 2025, 405: 1155-1166. PMID: 40086457, DOI: 10.1016/s0140-6736(24)02847-2.Peer-Reviewed Original ResearchDrug-susceptible tuberculosisTreatment outcomesPoor treatment outcomesPrimary outcomeDigital adherence technologiesIntervention armCluster randomised trialIntention-to-treat populationStandard of care armTuberculosis treatment outcomesDocumented treatment failureLoss to follow-upStandard of careAdherence technologiesTreatment failureTreatment startAdult patientsFollow-upPatientsTreatment statusPatient outcomesCare armTuberculosisMedicationTrialsKleptomania on the impulsive–compulsive spectrum. Clinical and therapeutic considerations for women
Munguía L, Baenas-Soto I, Granero R, Fábregas-Balcells M, Gaspar-Pérez A, Rosinska M, Potenza M, Cuquerella Á, Tapia-Martínez J, Cabús-Grange R, Taranilla-Castro A, Macharé-Alberni M, Talón-Navarro M, Fernández-Aranda F, Jiménez-Murcia S. Kleptomania on the impulsive–compulsive spectrum. Clinical and therapeutic considerations for women. Scientific Reports 2025, 15: 7886. PMID: 40050325, PMCID: PMC11885670, DOI: 10.1038/s41598-025-85705-9.Peer-Reviewed Original ResearchConceptsImpulsive-compulsive spectrumDSM-5 criteriaClinical groupsDSM-5Personality featuresSemi-structured clinical interviewTreatment outcomesHarm avoidance scoresCognitive behavioral treatmentHealthy control individualsSample of female patientsImpact treatment outcomesPoor treatment outcomesCompulsive featuresBehavioral treatmentHigher impulsivityAvoidance scoresClinical interviewKleptomaniaInvestigate treatment outcomesCharacteristics of peopleFemale participantsPsychopathologyClinical samplesTreatment approachesIdentification and external validation of a problem cannabis risk network
Lichenstein S, Kiluk B, Potenza M, Garavan H, Chaarani B, Banaschewski T, Bokde A, Desrivières S, Flor H, Grigis A, Gowland P, Heinz A, Brühl R, Martinot J, Paillère Martinot M, Artiges E, Nees F, Orfanos D, Poustka L, Hohmann S, Holz N, Baeuchl C, Smolka M, Vaidya N, Walter H, Whelan R, Schumann G, Pearlson G, Yip S. Identification and external validation of a problem cannabis risk network. Biological Psychiatry 2025 PMID: 39909136, DOI: 10.1016/j.biopsych.2025.01.022.Peer-Reviewed Original ResearchAlcohol use outcomesCannabis useNeural mechanismsSample of treatment-seeking adultsNeural mechanisms of riskTreatment-seeking adultsCannabis use disorderNon-clinical sampleMechanisms of riskFunctional connectivity dataSample of adolescentsTreatment outcomesAssociated with harmful outcomesPoor treatment outcomesAddiction severityUse disorderEmerging adulthoodWhole-brainCannabisCollege studentsBrain developmentConnectivity dataIdentified networksTreatment approachesAdults
2024
Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice
Brand M, Antons S, Bőthe B, Demetrovics Z, Fineberg N, Jimenez-Murcia S, King D, Mestre-Bach G, Moretta T, Müller A, Wegmann E, Potenza M. Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice. American Journal Of Psychiatry 2024, 182: 155-163. PMID: 39659159, DOI: 10.1176/appi.ajp.20240092.Peer-Reviewed Original ResearchBehavioral addictionsAddictive behaviorsGaming disorderDisorders due to addictive behaviorsCompulsive sexual behavior disorderCompulsive buying-shopping disorderAttention deficit hyperactivity disorderCognitive-behavioral therapyBuying-shopping disorderSexual behavior disorderEmpirical supportInternet gaming disorderDeficit hyperactivity disorderPoor treatment outcomesResearch to clinical practiceDSM-5Gambling disorderICD-11Psychiatric disordersHyperactivity disorderBehavior problemsBehavioral disordersAddictionDiagnostic instrumentsEfficacious treatmentMolecular Epidemiology of Isoniazid-resistant M tuberculosis in Port-au-Prince, Haiti
Walsh K, Lee M, Chaguza C, Pamphile W, Royal G, Escuyer V, Pape J, Fitzgerald D, Cohen T, Ocheretina O. Molecular Epidemiology of Isoniazid-resistant M tuberculosis in Port-au-Prince, Haiti. Open Forum Infectious Diseases 2024, 11: ofae421. PMID: 39119477, PMCID: PMC11306977, DOI: 10.1093/ofid/ofae421.Peer-Reviewed Original ResearchCulture-positive pulmonary tuberculosisIsoniazid-resistant isolatesHR-TBIsoniazid-resistant M. tuberculosisPulmonary tuberculosisIsoniazid resistanceMutations associated with INH resistanceTransmission clustersGenoType MTBDRplus assayINH-resistant isolatesIsoniazid-susceptible isolatesPhenotypic isoniazid resistanceRifampin-susceptible tuberculosisSingle nucleotide polymorphism distancesMolecular epidemiologyAssociated with poor treatment outcomesWhole-genome sequencingM. tuberculosisPutative transmission clustersPoor treatment outcomesMTBDRplus assayGenoType MTBDRplusCulture-based testsINH resistanceTuberculosis clinicAn emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria
Chen L, Kang Z, Shen J, Zhao R, Miao Y, Zhang L, Zheng Z, Zhang Z, Liu N, Wang C, Fang H, Zhou J, Wang Y, Liu Z, Yang Y, Chen Q. An emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria. Science Bulletin 2024, 69: 2565-2579. PMID: 38918142, DOI: 10.1016/j.scib.2024.06.016.Peer-Reviewed Original ResearchConceptsF. nucleatumColorectal cancerEffective antigen presentationEnhance chemotherapy efficacyT cell activationReduce cancer metastasisPoor treatment outcomesIncreased cancer cell growthCancer cell growthOral anaerobesDendritic cellsFusobacterium nucleatumChemotherapy efficacyAntitumor effectAntigen presentationBiomimetic nanovaccinesEnhanced chemotherapyNanovaccineAlum adjuvantCpG oligonucleotidesTreatment outcomesImmune responseImmune progressionTherapeutic effectVaccine effectivenessPredictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records
Ryuk D, Pelissari D, Alves K, Oliveira P, Castro M, Cohen T, Sanchez M, Menzies N. Predictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records. BMC Infectious Diseases 2024, 24: 531. PMID: 38802744, PMCID: PMC11129366, DOI: 10.1186/s12879-024-09417-7.Peer-Reviewed Original ResearchConceptsTreatment outcomesFactors associated with unsuccessful treatment outcomesHigher risk of poor treatment outcomeTB treatmentRisk of poor treatment outcomesUnsuccessful treatmentEffectiveness of TB treatmentAssociated with unsuccessful treatmentUnsuccessful treatment outcomesTuberculosis treatment outcomesDrug-susceptible TBHealth system levelMultivariate logistic regression modelService-related factorsTB drug resistanceComorbid health conditionsHealth-related behaviorsCategorizing treatment outcomesPatient-level factorsClinical examination resultsNational Disease Notification SystemPoor treatment outcomesDisease notification systemHIV infectionLogistic regression models
2023
A Pilot Trial of SPACE (Supportive Parenting for Anxious Childhood Emotions) in Autism
Rozenblat S, Shimshoni Y, Lebowitz E, Perez M, Koller J. A Pilot Trial of SPACE (Supportive Parenting for Anxious Childhood Emotions) in Autism. Child Psychiatry & Human Development 2023, 56: 249-263. PMID: 37353645, DOI: 10.1007/s10578-023-01555-4.Peer-Reviewed Original ResearchFamily accommodationAnxious Childhood EmotionsAverage cognitive abilityCognitive behavior therapySymptom severityAnxiety symptom severityChildhood EmotionsChildhood anxietyCognitive abilitiesSupportive parentingChild distressAutistic populationManualized treatmentAutistic childrenReliable changeGreater functional impairmentAutismWeekly sessionsAnxietyPoor treatment outcomesPreliminary evidencePreliminary efficacyDistressPilot trialCaregiver burdenThe Effect of Cognitive Behavioral Therapy on Impulsivity in Addictive Disorders: a Narrative Review
Loya J, Benitez B, Kiluk B. The Effect of Cognitive Behavioral Therapy on Impulsivity in Addictive Disorders: a Narrative Review. Current Addiction Reports 2023, 10: 485-493. PMID: 38269068, PMCID: PMC10805411, DOI: 10.1007/s40429-023-00491-6.Peer-Reviewed Original ResearchCognitive behavioral therapyBehavioral therapySubstance useAddictive disordersFuture clinical trialsPoor treatment outcomesEvidence-based treatmentsMeasures of impulsivityCycle of addictionCBT effectsRisk factorsClinical trialsTreatment outcomesRecent FindingsThereNarrative reviewCharacteristics of addictionLimited evidenceRange of addictionsAssessment of impulsivityTherapyAddictionTrialsDisordersImpulsivityAddictive behaviors
2022
Treatment response trajectories in residential PTSD programs for veterans: A national cohort investigation
Grau P, Sripada R, Pietrzak R, Ganoczy D, Harpaz-Rotem I. Treatment response trajectories in residential PTSD programs for veterans: A national cohort investigation. Journal Of Anxiety Disorders 2022, 92: 102645. PMID: 36334317, DOI: 10.1016/j.janxdis.2022.102645.Peer-Reviewed Original ResearchConceptsEvidence-based psychotherapiesThree-group trajectory modelTreatment outcomesTreatment responseTime of admissionPoor treatment outcomesPoor treatment responseNon-white raceResidential PTSD programsSubset of veteransPTSD treatment outcomesResidential PTSD treatmentPain severityCohort investigationPTSD careNational cohortFull cohortPTSD treatmentTherapeutic gainTreatment dropoutSymptom trajectoriesVeterans AffairsPTSD programTreatment response trajectoriesTreatment trajectoriesRisk for PTSD symptom worsening during new PTSD treatment episode in a nationally representative sample of treatment-seeking U.S. veterans with subthreshold PTSD
Gross GM, Pietrzak RH, Hoff RA, Katz IR, Harpaz-Rotem I. Risk for PTSD symptom worsening during new PTSD treatment episode in a nationally representative sample of treatment-seeking U.S. veterans with subthreshold PTSD. Journal Of Psychiatric Research 2022, 151: 304-310. PMID: 35526446, DOI: 10.1016/j.jpsychires.2022.04.040.Peer-Reviewed Original ResearchConceptsSymptom worseningRisk factorsSubthreshold PTSDPTSD symptom clustersSymptom clustersPTSD symptomsHealth care utilizationPTSD specialty clinicPoor treatment outcomesUnited States veteransBinary logistic regressionAdjusted analysisCare utilizationTreatment episodesRepresentative sampleSpecialty clinicSignificant symptomsTreatment outcomesSignificant worseningStates veteransSubthreshold symptomsEligible veteransNew episodesOutcome assessmentDiagnostic threshold
2021
Sex Differences across Retrospective Transitions in Posttraumatic Stress and Substance Use Disorders
Peltier MR, Roberts W, Verplaetse TL, Zakiniaeiz Y, Burke C, Moore KE, McKee SA. Sex Differences across Retrospective Transitions in Posttraumatic Stress and Substance Use Disorders. Journal Of Dual Diagnosis 2021, 18: 11-20. PMID: 34965199, PMCID: PMC9086923, DOI: 10.1080/15504263.2021.2016027.Peer-Reviewed Original ResearchConceptsDrug use disordersOngoing posttraumatic stress disorderSubstance use disordersSUD/PTSDPosttraumatic stress disorderNew PTSD diagnosisImpact of sexUse disordersDiagnosis of SUDPast-year substance use disorderPTSD diagnosisConcurrent substance use disordersDiagnosis of PTSDPoor treatment outcomesNational Epidemiologic SurveyBidirectional relationshipSex-specific analysesPotential sex-specific differencesTreatment outcomesAlcohol Use and the Risk of Communicable Diseases
Morojele NK, Shenoi SV, Shuper PA, Braithwaite RS, Rehm J. Alcohol Use and the Risk of Communicable Diseases. Nutrients 2021, 13: 3317. PMID: 34684318, PMCID: PMC8540096, DOI: 10.3390/nu13103317.Peer-Reviewed Original ResearchConceptsCommunicable diseasesTreatment outcomesSevere acute respiratory syndrome coronavirus 2Respiratory infection/pneumoniaAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Alcohol useDisability-adjusted life yearsSyndrome coronavirus 2Poor treatment outcomesCOVID-19 infectionAlcohol use disorderGlobal health concernIndividual-level interventionsDifferent communicable diseasesTB deathsImmunodeficiency virusCoronavirus 2Severe illnessUse disordersPneumoniaHeavy drinkersLife yearsHIV researchTuberculosisRacial Disparities in Clinical Outcomes of Veterans Affairs Residential PTSD Treatment Between Black and White Veterans
Gross GM, Smith N, Holliday R, Rozek DC, Hoff R, Harpaz-Rotem I. Racial Disparities in Clinical Outcomes of Veterans Affairs Residential PTSD Treatment Between Black and White Veterans. Psychiatric Services 2021, 73: 126-132. PMID: 34369806, DOI: 10.1176/appi.ps.202000783.Peer-Reviewed Original ResearchConceptsResidential Rehabilitation Treatment ProgramPosttraumatic stress disorderWhite veteransRacial disparitiesClinical outcomesBlack veteransSymptoms of PTSDPoor clinical outcomeRehabilitation treatment programRecurrence 4 monthsPoor treatment outcomesMental health treatmentPublic health issuePTSD symptom reductionResidential PTSD treatmentMental health researchTreatment outcomesPrevalence ratesSymptom reductionHealth treatmentHealth outcomesPTSD treatmentDemographic dataSymptom changeTreatment programSubstance Use, Gambling, Binge‐Eating, and Hypersexuality Symptoms Among Patients Receiving Opioid Agonist Therapies
Carr MM, Ellis JD, Saules KK, Page JL, Staples A, Ledgerwood DM. Substance Use, Gambling, Binge‐Eating, and Hypersexuality Symptoms Among Patients Receiving Opioid Agonist Therapies. American Journal On Addictions 2021, 30: 343-350. PMID: 33783065, PMCID: PMC8243775, DOI: 10.1111/ajad.13149.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAgonist therapySeverity of symptomsDrug useTobacco useAlcohol useOpioid use disorderPoor treatment outcomesAdverse childhood eventsBinge-eating symptomsMost patientsOutpatient clinicPsychiatric comorbiditySignificant symptomsTreatment outcomesAddictive behaviorsUse disordersPatientsNegative binomial regressionSymptomsTherapyBinge eatingHigher depressionSubstance useSeverity
2020
Examining Self-Weighing Behaviors and Associated Features and Treatment Outcomes in Patients with Binge-Eating Disorder and Obesity with and without Food Addiction
Wiedemann AA, Ivezaj V, Gueorguieva R, Potenza MN, Grilo CM. Examining Self-Weighing Behaviors and Associated Features and Treatment Outcomes in Patients with Binge-Eating Disorder and Obesity with and without Food Addiction. Nutrients 2020, 13: 29. PMID: 33374870, PMCID: PMC7823454, DOI: 10.3390/nu13010029.Peer-Reviewed Original ResearchConceptsBinge-eating disorderFood addictionFrequency of weighingShape/weightRelated perceptionsEating Disorder ExaminationBinge Eating DisorderBehavioral weight loss treatmentWeight loss treatmentDisorder ExaminationLess acceptanceFrequent weighingPoor treatment outcomesTreatment outcomesNegative reactionsBWL treatmentParticipantsLoss treatmentMixed effects modelsPerceptionFA statusAddictionAssociated featuresGreater likelihoodIndividualsTime to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China
Li Q, Lu M, Hsieh E, Wu L, Wu Y, Wang M, Wang L, Zhao G, Xie L, Qian HZ. Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China. Medicine 2020, 99: e23649. PMID: 33327347, PMCID: PMC7738096, DOI: 10.1097/md.0000000000023649.Peer-Reviewed Original ResearchConceptsInitial sputum culture conversionSputum culture conversionPoor treatment outcomesSuccessful treatment outcomeTreatment outcomesCulture conversionMDR-TBMultidrug-resistant tuberculosis patientsCox proportional hazards regressionMDR-TB treatmentMDR-TB patientsRetrospective cohort studyKaplan-Meier methodTreatment success rateInitiation of treatmentMultidrug-resistant tuberculosisProportional hazards regressionConsecutive negative culturesRisk of transmissionCohort studyTuberculosis patientsTreatment failureHazards regressionOutpatient treatmentInpatient treatmentModeration of Prazosin’s Efficacy by Alcohol Withdrawal Symptoms
Sinha R, Wemm S, Fogelman N, Milivojevic V, Morgan PM, Angarita GA, Hermes G, Fox HC. Moderation of Prazosin’s Efficacy by Alcohol Withdrawal Symptoms. American Journal Of Psychiatry 2020, 178: 447-458. PMID: 33207935, PMCID: PMC8119326, DOI: 10.1176/appi.ajp.2020.20050609.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-1 Receptor AntagonistsAdultAlcohol AbstinenceAlcoholismAnxietyCentral Nervous System DepressantsCounselingCravingDepressionDouble-Blind MethodEthanolFemaleHumansMaleMiddle AgedPrazosinProof of Concept StudySelf-Help GroupsSleep Wake DisordersSubstance Withdrawal SyndromeTreatment OutcomeConceptsAlcohol withdrawal symptomsHeavy drinking daysAlcohol use disorderDrinks/dayWithdrawal symptomsDrinking daysSecondary outcomesPrazosin efficacyAlcohol cravingSelf-reported drinking daysTreatment of AUDEfficacy of prazosinWithdrawal symptom scoresPoor treatment outcomesGlobal disease burdenCurrent alcohol dependencePrimary outcomeTreat analysisAlcohol use outcomesAlcohol intakeSymptom scoresWeek 12Prognostic indicatorDisease burdenSleep disturbancesHispanic participants in the National Institute on Drug Abuse’s Clinical Trials Network: A scoping review of two decades of research
Eghaneyan BH, Sanchez K, Haeny AM, Montgomery L, Lopez-Castro T, Burlew AK, Rezaeizadeh A, Killian MO. Hispanic participants in the National Institute on Drug Abuse’s Clinical Trials Network: A scoping review of two decades of research. Addictive Behaviors Reports 2020, 12: 100287. PMID: 32637563, PMCID: PMC7330873, DOI: 10.1016/j.abrep.2020.100287.Peer-Reviewed Original ResearchClinical Trials NetworkSubstance abuse treatmentTreatment outcomesNational Drug Abuse Treatment Clinical Trials NetworkTrials NetworkAbuse treatmentDrug Abuse Clinical Trials NetworkEffective interventionsPoor treatment outcomesHispanic populationSubstance use disordersPatient characteristicsClinical trialsTobacco useTreatment accessUse disordersHispanic participantsGreater riskTreatment participationSystematic searchSubstance useTreatment issuesRelevant studiesInfluence utilizationLess likelihood
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply